First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to determine:
The safety of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin, or
docetaxel with carboplatin and any side effects that might be associated with the combination
of these drugs.
Whether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and
carboplatin can help participants with non-small cell lung cancer (NSCLC) live longer,
compared with the combination of docetaxel and carboplatin.
Whether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and
carboplatin can make your tumor smaller or disappear, and for how long, compared with the
combination of docetaxel and carboplatin.
The effects of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin or
docetaxel with carboplatin have on your disease related symptoms.
The relation of smoking history and hormone replacement therapy (for women only) may have to
your lung cancer treatment results.
The effects of certain genes and proteins in samples of your blood and tumor tissue in order
to learn more about NSCLC and how enzastaurin works in the body.